MajesTEC-5 (MMY2003 / GMMG-HD10 / DSMM-XX) Trial

[Slide 1] GMMG-HD10/DSMM-XX/MajesTEC-5: Study Design Key eligibility Induction (6 x 28-day cycles)a Maintenanceᵇ,ᶜ (x 18 cycles) Primary endpoints: criteria: AEs, SAEs Arm A (n=10): TE NDMM Tec (1.5 mg/kg QW)-DR Select secondary ECOG PS score of 0-2 Arm A1 (n=20): HDT + ASCT endpoints: Aged 18-70 years Tec-D MRD negativity Tec (3 mg/kg Q4W)-DR (10-5 and 10-6) ORR >CR Arm B (n=19): >VGPR Tec (3 mg/kg Q4W)-DVR Stem cell yield C1 C2 C3 C4 C5 C6 MRD 10-5 via NGF MRD MRD MRD 10⁻⁶ via NGS Tec (Cycle 1): Tec step-up dosing (0.06 and 0.3 mg/kg on Days 2 and 4) + 1.5 mg/kg on Days 8 and 15e - Tec (Cycles 2-6): 1.5 mg/kg QW on Day 1 (ArmA); 3 mg/kg Q4W on Day 1 (Arm A1 and B) D: 1800 mg SC per label (QW for Cycles 1-2; Q2W for Cycles 3-6) V: 1.3 mg/m² SC QW R: 25 mg PO daily starting in Cycle 2 (Days 1-21) d: 20 mg (PO or IV) in Cycles 1-4 (Arm A) or Cycles 1-2 (Arm A1/B) only "Stem cell collection was planned after 3 cycles of induction Following maintenance therapy. patients could receive additional SoC maintenance treatment per institutional standard and local investigator decision Maintenance treatment can be discontinued when 12 months of sustained MRD negativity (10 have been observed beginning in induction Planned maintenance treatment in Arm Awas Teo-DR. A protocol amendment permitted patients initially assigned to Teo-DR maintenance to receive Tec-D maintenance per investigator's choice (patients who started Tec-DR may have discontinued R to receive Tec- per investigator's choice). "Patients in Arm A received an additional dose of Tec1 1.5 mg/kg on Day 22 AE, adverse event; ASCT, autologous stem cell transplant; CR, complete response D. daratumumab d, dexamethasone; DSMM Deutsche Studiengruppe Multiples Myelom: ECOG PS, Eastern Cooperative Oncology Group performance status: GMMG, German-speaking Myeloma Multicenter Group: HDT, high-dose therapy; MRD. minimal residual disease NDMM newly diagnosed multiple myeloma; NGF, next-generation flow cytometry: NGS, next-generation sequencing ORR, overall response rate; QW. weekly; Q2W. every 2 weeks; Q4W. every 4 weeks; R. lenalidomide; SAE serious adverse event; SoC. standard of care, TE, trans plant-eligible; Tec, teclistamab; V. bortezomib; VGPR, very good partial response 5 Presented by MS Raab at the 22nd International Myeloma Society (IMS) Annual Meeting: September 17-20, 2025; Toronto, Canada --- [Slide 2] GMMG-HD10/DSMM-XX/MajesTEC-5: Response Ratesᵃ ORR ORR ORR 100 100 100 100 90 80 70 ≥CR 60 73.7 73.7 Patients (%) sCR ≥CR ≥VGPR ≥CR ≥VGPR ≥VGPR 50 100 95 CR 100 100 95 95 94.7 VGPR 40 PR 30 20 21.1 10 0 5 5.3 Arm A: Arm A1: Arm B: Tec (QW)-DR Tec (Q4W)-DR Tec (Q4W)-DVR n=10 n=20 n=19 100% of patients responded by the end of induction Response was assessed by investigators based on IMWG criteria, with a confirmed response requiring >2 consecutive identical response assessments ORR was defined as >PR. CR, complete response; D, daratumumab; DSMM, Deutsche Studiengruppe Multiples Myelom; GMMG, German-speaking Myeloma Multicenter Group; IMWG, International Myeloma Working Group; ORR, overall response rate; PR, partial response; QW, weekly, Q4W, every 4 weeks; R, lenalidomide; sCR, stringent complete response; Tec, teclistamab; V, bortezomib; VGPR, very good partial response. 12 Presented by MS Raab at the 22nd International Myeloma Society (IMS) Annual Meeting: September 17-20, 2025; Toronto, Canada --- [Slide 3] GMMG-HD10/DSMM-XX/MajesTEC-5: MRD Negativity (10-5)a in the MRD-Evaluable Analysis Set MRD-evaluable population: all patients with an available MRD test (positive or negative)b - Only 1 patient was not evaluable for MRD throughout induction (Cycle 3 or 6) due to discontinuation before Cycle 3 Arm A: Tec (QW)-DR Arm A1: Tec (Q4W)-DR Arm B: Tec (Q4W)-DVR 100 90 MRD-evaluable patients (%) 80 70 60 50 100 100 100 100 100 100 40 30 20 10 n=10 n=10 n=19° n=19d n=17e n=17' 0 Cycle 3 Cycle 6 Cycle 3 Cycle 6 Cycle 3 Cycle 6 With completion of induction, 100% MRD negativity (10-5) continues to be observed in MRD-evaluable patients, regardless of depth of response RD-negativity rate was defined as the proportion of patients who achieved MRD negativity (10-5) per NGF, regardless of response (ie, not all patients achieved CR). Excluding those who were not tested, indeterminate, or had no baseline done detected (NGS). One patient was not tested One patient had discontinued after completing Cycle 3. "One patient was not tested, and 1 had discontinued before completing Cycle 3. One patient had discontinued before completing Cycle 3, and 1 had an indeterminate result. CR, complete response; D, daratumumab; DSMM, Deutsche Studiengruppe Multiples Myelom: GMMG, German-speaking Myeloma Multicenter Group; MRD, minimal residual disease; NGF, nexd-generation flow cytometry, NGS, next-generation sequencing; QW, weekly, Q4W, every 4 weeks; R, lenalidomide; Tec, teclistamab; V, bortezomib. 13 Presented by MS Raab at the 22nd International Myeloma Society (IMS) Annual Meeting: September 17-20, 2025; Toronto, Canada --- [Slide 4] GMMG-HD10/DSMM-XX/MajesTEC-5: Infections Arm A: Arm A1: Arm B: 18 (36.7%) patients had Tec (QW)-DR Tec (Q4W)-DR Tec (Q4W)-DVR Total grade 3/4 infectionsᵇ (n=10) (n=20) (n=19) (N=49) All Grade All Grade All Grade All - No discontinuations due to infection Grade 3/4 TEAE, n (%)a grade 3/4 grade 3/4 grade 3/4 grade - No grade 5 infections Any infection 10 (100) 4 (40) 18 (90) 10 (50) 11 (57.9) 4 (21.1)b 39 (79.6) 18 (36.7)b Hypogammaglobulinemia® reported in 45 (91.8%) patients Infections - 44 (89.8%) patients received ≥1 URTI 6 (60) 0 8 (40) 1 (5) 6 (31.6) 0 20 (40.8) 1 (2) dose of IVIg COVID-19 2 (20) 0 4 (20) 1 (5) 3 (15.8) 2 (10.5) 9 (18.4) 3 (6.1) Stringent infection prophylaxis was strongly recommended,e including Nasopharyngitis 3 (30) 0 2 (10) 0 2 (10.5) 0 7 (14.3) 0 Ig replacement Pneumonia 1 (10) 1 (10) 0 0 2 (10.5) 2 (10.5) 3 (6.1) 3 (6.1) Low patient numbers and relatively RTI 0 0 1 (5) 0 2 (10.5) 0 3 (6.1) 0 short follow-up time may account for differing infection rates across Bronchitis 2 (20) 0 0 0 0 0 2 (4.1) 0 arms AEs are graded according to the NCI-CTCAE Version 5.0. The median follow-up was 7.3 (3.1-14.5) months. One patient had a grade 3 "unknown" infection that was reported under the "uncoded" category. Infections reported in > 10% of patients in any arm. "Includes patients with 21 TEAE of hypogammaglobulinemia or a post-baseline IgG value <400 mg/dL. Additional recommended measures included prophylaxis for Pneumocystis jirovecii pneumonia and herpes zoster reactivation as well as routine antibiotic prophylaxis. D, daratumumab; DSMM, Deutsche Studiengruppe Multiples Myelom; GMMG, German-speaking Myeloma Multicenter Group; Ig. immunoglobulin; Mg. intravenous immunoglobulin; NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; QW, weekly; Q4W, every 4 weeks; R, lenalidomide; RTI, respiratory tract infection; TEAE, treatment-emergent adverse event; Tec, teclistamab; URTI, upper respiratory tract infection; V. bortezomib. 10 Presented by MS Raab at the 22nd International Myeloma Society (IMS) Annual Meeting: September 17-20, 2025; Toronto, Canada

[Slide 1] GMMG-HD10/DSMM-XX/MajesTEC-5: MRD Negativity (10⁻⁶)a in the MRD-Evaluable Analysis Setb Arm A: Tec (QW)-DR Arm A1: Tec (Q4W)-DR Arm B: Tec (Q4W)-DVR 100 When combining all patients 90 across all arms (n=49), 80 MRD-evaluable patients (%) cumulative MRD-negativity rate 70 by end of induction in the 60 efficacy analysis set was 98.0% 50 100 100 100 85.7% (42/49) of patients 40 achieved >CR and MRD 30 negativity at Cycle 6 (≤10⁻⁵) 20 10 n=10 n=19c n=17d 0 Cycle 6 Cycle 6 Cycle 6 100% of patients in the MRD-evaluable population,ᵇ regardless of depth of response, achieved MRD negativity (10-6) at Cycle 6 MRD-negativity rate was defined as the proportion of patients who achieved MRD negativity (10-6), regardless of response MRD-evaluable population defined as those patients with an available MRD test with a positive or negative result (excluding those who were not tested, were indeterminate or had no baseline clone detected [NGS]). One patient had discontinued after completing Cycle 3. One patient had discontinued before completing Cycle 3, and 1 had no baseline clone detected for NGS *Patients who achieved MRD negativity at 10-⁵ or 10-6 at any time on study (post-induction cycle 3 or cycle 6). D. daratumumab; DSMM, Deutsche Studiengruppe Multiples Myelom; GMMG, German-speaking Myeloma Multicenter Group; MRD, minimal residual disease NGF, next-generation flow cytometry; NGS, next-generation sequencing; QW, weekly; Q4W, every 4 weeks; R. lenalidomide; Tec, teclistamab; V. bortezomib 14 Presented by MS Raab at the 22nd International Myeloma Society (IMS) Annual Meeting: September 17-20. 2025; Toronto, Canada

[Slide 1] GMMG-HD10/DSMM-XX/MajesTEC-5: Study Design Key eligibility Induction (6 x 28-day cycles)a Maintenanceb,ᶜ (x 18 cycles) criteria: Arm A (n=10): TE NDMM Tec (1.5 mg/kg QW)-DR ECOG PS score of 0-2 Arm A1 (n=20): Aged 18-70 years Tec (3 mg/kg Q4W)-DR HDT + ASCT Tec-D Arm B (n=19): Tec (3 mg/kg Q4W)-DVR C1 C2 C3 C4 C5 C6 MRD MRD / . - --- [Slide 2] GMMG-HD10/DSMM-XX/MajesTEC-5: MRD Negativity (10-6)a in the MRD-Evaluable Analysis Setb Arm A: Tec (QW)-DR Arm A1: Tec (Q4W)-DR Arm B: Tec (Q4W)-DVR 100 When combining all patients 90 across all arms (n=49), 80 cumulative MRD-negativity rate MRD-evaluable patients (%) 70 by end of induction in the 60 efficacy analysis set was 98.0% 50 100 100 100 85.7% (42/49) of patients 40 achieved >CR and MRD 30 negativity at Cycle 6 (≤10⁻⁵) 20 10 n=10 n=19c n=17d 0 Cycle 6 Cycle 6 Cycle 6 100% of patients in the MRD-evaluable population,ᵇ regardless of depth of response, achieved MRD negativity (10-6) at Cycle 6 MRD negativity. of nations achieved defined as those patients an available --- [Slide 3] GMMG-HD10/DSMM-XX/MajesTEC-5: Infections Arm A: Arm A1: Arm B: 18 (36.7%) patients had Tec (QW)-DR Tec (Q4W)-DR Tec (Q4W)-DVR Total grade 3/4 infectionsᵇ (n=10) (n=20) (n=19) (N=49) All Grade All Grade All Grade All - No discontinuations due to infection Grade 3/4 TEAE, n (%)a grade 3/4 grade 3/4 grade 3/4 grade - No grade 5 infections Any infection 10 (100) 4 (40) 18 (90) 10 (50) 11 (57.9) 4 (21.1)b 39 (79.6) 18 (36.7)b Hypogammaglobulinemiad reported in 45 (91.8%) patients Infections - 44 (89.8%) patients received ≥1 URTI 6 (60) 0 8 (40) 1 (5) 6 (31.6) 0 20 (40.8) 1 (2) dose of IVIg COVID-19 2 (20) 0 4 (20) 1 (5) 3 (15.8) 2 (10.5) 9 (18.4) 3 (6.1) Stringent infection prophylaxis was strongly recommended,e including Nasopharyngitis 3 (30) 0 2 (10) 0 2 (10.5) 0 7 (14.3) 0 Ig replacement Pneumonia 1 (10) 1 (10) 0 0 2 (10.5) 2 (10.5) 3 (6.1) 3 (6.1) Low patient numbers and relatively RTI 0 0 1 (5) 0 2 (10.5) 0 3 (6.1) 0 short follow-up time may account for differing infection rates across Bronchitis 2 (20) 0 0 0 0 0 2 (4.1) 0 arms

[Slide 1] GMMG-HD10/DSMM-XX/MajesTEC-5: MRD Negativity (10-6)a in the MRD-Evaluable Analysis Setb Arm A: Tec (QW)-DR Arm A1: Tec (Q4W)-DR Arm B: Tec (Q4W)-DVR 100 When combining all patients 90 across all arms (n=49), 80 cumulative MRD-negativity rate® MRD-evaluable patients (%) 70 by end of induction in the 8 efficacy analysis set was 98.0% 50 100 100 100 85.7% (42/49) of patients 40 achieved >CR and MRD 30 negativity at Cycle 6 (≤10⁻⁵) 20 10 n=10 n=19° n°17° 0 Cycle 6 Cycle 6 Cycle 6 100% of patients in the MRD-evaluable population,ᵇ regardless of depth of response, achieved MRD negativity (10-5) at Cycle 6 and (sicluding - has was who delined - not RI be poporton - of polients who achoved MRS) (10-9) regardless of response. MRD. evaluable population defined as those patients with an available MRD last - 80 Issue Date for NOS Pateras resied, who achieved MRD or had to baseire done detected (NGS) *Doe patient has discontinued after completing Cycle 3. One polient had discontinged before a positive of negative 1 had Group, MRD, registrate a 10⁴ at any time on study (post induction cycle 3 or cycle 6) D, ow. OSMM Deumche Studengruppe Multiples completing Myslom Cycle GMMG, 3, and examal residual donese, NOF, not-generation for cytomosy, NOS NEXT monthly, Q4W every & weeks; R Imalidomida Tec. --- [Slide 2] GMMG-HD10/DSMM-XX/MajesTEC-51 MRD Negativity (10-⁵)ᵃ in the MRD-Evaluable Analysis Set MRD-evaluable population: all patients with an available MRD test (positive or negative)ᵇ - Only 1 patient was not evaluable for MRD throughout induction (Cycle 3 or 6) due to discontinuation before Cycle 3 Arm A: Tec (QW)-DR Arm A1: Tec (Q4W)-DR Arm B: Tec (Q4W)-DVR 100 90 MRD-evaluable patients (%) 80 70 60 50 100 100 100 100 100 100 40 30 20 10 n=10 0 n=10 n=19° n=19d n=17° n=17' Cycle 3 Cycle 6 Cycle 3 Cycle 6 Cycle 3 Cycle 6 With completion of induction, 100% MRD negativity (10-5) continues to be observed in MRD-evaluable patients, regardless of depth of response Insure SED regative - was adinat Cen as the provide proportion - not of Instad patients One was belowed achieved had MRD regalizity (189) per NOF, regardiess of - Fax not at patents actived CR) "Excluding Thosa who --- [Slide 3] GMMG-HD10/DSMM-XX/MajesTEC-5: Infections Arm A: Arm A1: Arm B: 18 (36.7%) patients had Tec (QW)-DR Tec (Q4W)-DR Tec (Q4W)-DVR Total grade 3/4 infectionsᵇ (n=10) (п=20) (n=19) (N=49) All Grade All Grade All Grade All - No discontinuations due to Infection Grade 3/4 TEAE, n (%)* grade 3/4 grade 3/4 grade 3/4 grade - No grade 5 infections Any Infection 10 (100) 4 (40) 18 (90) 10 (50) 11 (57.9) 4 (21.1) 39 (79.6) 18 (36.7)b Hypogammaglobulinemia® reported in 45 (91.8%) patients Infectionsᶜ - 44 (89.8%) patients received ≥1 URTI 6 (60) 0 8 (40) 1 (5) 6 (31.6) 0 20 (40.8) 1 (2) dose of IVlg COVID-19 2 (20) 0 4 (20) 1 (5) 3 (15.8) 2 (10.5) 9 (18.4) 3 (6.1) Stringent infection prophylaxis was Nasopharyngitis 3 (30) 0 2 (10) 0 2(10.5) 0 7 (14.3) 0 strongly recommended, including Ig replacement Pneumonia 1 (10) 1 (10) 0 0 2(10.5) 2 (10.5) 3(6.1) 3 (6.1) Low patient numbers and relatively RTI 0 0 1 (5) 0 2 (10.5) 0 3 (6.1) 0 short follow-up time may account Bronchitis 2 (20) 0 0 0 0 0 2 (4.1) 0 for differing infection rates across arms ALA 10% - . graded patents according n any - to the Recludes NO-CTORE patients Version with at 10 TEAE The median of blow-up - 73 or I-14.5) a post months baseine One g0 patient value <00 had a mg/dl grade Additional 3 'ustrown' recommended infection that measures was reported included under prophytics the uncoded Ry Promocysts calogory Infections reported

[Slide 1] Post-Induction Outcomes and Updated Minimal Residual Disease Analysis From GM MG GMMG-HD10/DSMM-XX (MajesTEC-5): a Study deutsche studiengruppe of Teclistamab-Based Induction Regimens in multiples envelops Newly Diagnosed Multiple Myeloma (NDMM)* dsmm mong mudes - *ClinicalTrials.gov Identifier: NCT05695508; sponsored by the University of Heidelberg Medical Center and in collaboration with Johnson & Johnson Marc S Raab1, Niels Weinhold1, K Martin Kortüm², Jan Krönke³, Lilli Podola¹, Uta Bertsch1, hops Julia Mersi², Stefanie Huhn1, Michael Hundemer1, Roland Fenk4, Katja Weisel⁵, Alexander Brobeil°, The OR code is intended 33 provide scientific Elias K Mai1, Natalie Schub⁷, Florian Bassermann8, Monika Engelhardt9, Mathias Hänel10, information for individual and the information should not be attered or Hans Salwender11, Raphael Teipel¹², Mohamed Amine Bayar13, Elena Ershova14, reproduced as any way Bas D Koster¹⁵, Hartmut Goldschmidt1, Hermann Einsele², Leo Rasche² 'Heidelberg Myeloma Center, Department of Medicine V. Heldelberg University Hospital and Medical Faculty Heldelberg, Heldelberg, Germany; Department of Internal Medicine 11, University Hospital of Würzburg, Würzburg, Germany; Department for Hematology, Oncology, and Tumor immunology, Charité Universitätsmedizin Bertin, Germany; Department for Hematology, Oncology and Clinical Immunology, Medical Faculty, Heinrich Heine University Dusseldorf, Moorenstr 5, 40225, Dusseldorf, Germany: University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Institute of Pathology, University Hospital Heldelberg, Heldelberg, Germany: Department of Internal Medicine 11, Division of Stem Cell Transplantation and Immunotherapy, UKSH Campus Kiel, Kiel, Germany; Department of Medicine III, TUM Klinikum, Technische Universität München, München, Germany; German Cancer Consortium (OKTK), German Cancer Research Center (DKFZ), Heldelberg, Germany; Department of Hematology, Oncology and Stem Cell Transplantation, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; "Department of internal Medicine 111, Klinikum Chemnitz, Chemnitz, Germany; "Asklepios Tumorzentrum Hamburg, AK Altona and AK St Georg, Hamburg, Germany; Medizinische Klinik und Poliklinik 1, Universitätsklinikums Carl Gustav Carus an der TU Dresden, Dresden, Germany; PJohnson & Johnson, Parts, France; "Johnson & Johnson, Beerse, Belgium; "Johnson 5 Johnson, Leiden, The Netherlands. Presented by MS Raab at the 22nd International Myeloma Society (IMS) Annual Meeting: September 17-20, 2025; Toronto, Canada --- [Slide 2] GMMG-HD10/DSMM-XX/MajesTEC-5: Study Design Key eligibility Induction (6 x 28-day cycles)a Maintenanceᵇ,ᶜ (x 18 cycles) Primary endpoints: criteria: Arm A (n=10): AEs, SAEs TE NDMM Tec (1.5 mg/kg QW)-DR Select secondary ECOG PS score of 0-2 Arm A1 (n=20): Tec (3 mg/kg Q4W)-DR HDT + ASCT endpoints: Aged 18-70 years Tec-D MRD negativity (10⁻⁵ and 10⁻⁶) ORR Arm B (n=19): >CR >VGPR Tec (3 mg/kg Q4W)-DVR Stem cell yield C1 C2 C3 C4 C5 C6 MRD 10⁻⁵ via NGF MRD MRD MRD 10⁻⁶ via NGS Tec (Cycle 1): Tec step-up dosing (0.06 and 0.3 mg/kg on Days 2 and 4) + 1.5 mg/kg on Days 8 and 15ᵉ - Tec (Cycles 2-6): 1.5 mg/kg QW on Day 1 (Arm A); 3 mg/kg Q4W on Day 1 (Arm A1 and B) D: 1800 mg SC per label (QW for Cycles 1-2; Q2W for Cycles 3-6) V: 1.3 mg/m2 SC QW R: 25 mg PO daily starting in Cycle 2 (Days 1-21) d: 20 mg (PO or IV) in Cycles 1-4 (Arm A) or Cycles 1-2 (Arm A1/B) only Stem cell collection was planned after 3 cycles of induction. Following maintenance therapy, patients could receive additional SoC maintenance treatment per institutional standard and local investigator decision. Maintenance treatment an be discontinued when 12 months of sustained MRD negativity (10-4) have been observed, beginning in induction Planned maintenance treatment in Arm A was Tec-DR A protocol amendment permitted patients initially assigned to Tec-DR saintenance to receive Tec-D maintenance per investigator's choice (patients who started Tec-DR may have discontinued R to receive Tec-D per investigator's choice). Patients in Arm A received an additional dose of Tec 1.5 mg/kg on Day 22. E, adverse event; ASCT, autologous stem cell transplant; CR, complete response, D, daratumumab; d, dexamethasone; DSMM, Deutsche Studiengruppe Multiples Myelom; ECOG PS, Eastern Cooperative Oncology Group performance status; MMG, German-speaking Myeloma Multicenter Group; HDT, high-dose therapy, MRD, minimal residual disease; NDMM, newly diagnosed multiple myeloma; NGF, next-generation flow cytometry; NGS, next-generation sequencing ORR, overall esponse rate; QW, weekly; Q2W, every 2 weeks; Q4W, every 4 weeks; R, lenalidomide; SAE, serious adverse event, SoC, standard of care; TE, transplant-eligible; Tec, teclistamab; V, bortezomib; VGPR, very good partial response 5 Presented by MS Raab at the 22nd International Myoloma Society (IMS) Annual Meeting: September 17-20. 2025; Toronto, Canada --- [Slide 3] GMMG-HD10/DSMM-XX/MajesTEC-5: MRD Negativity (10-6)a in the MRD-Evaluable Analysis Setb Arm A: Tec (QW)-DR Arm A1: Tec (Q4W)-DR Arm B: Tec (Q4W)-DVR 100 When combining all patients 90 across all arms (n=49), 80 cumulative MRD-negativity rate® MRD-evaluable patients (%) 70 by end of induction in the 60 efficacy analysis set was 98.0% 50 100 100 100 85.7% (42/49) of patients 40 achieved ≥CR and MRD 30 negativity at Cycle 6 (≤10⁻⁵) 20 10 n=10 n=19° n=17d 0 Cycle 6 Cycle 6 Cycle 6 100% of patients in the MRD-evaluable population,ᵇ regardless of depth of response, achieved MRD negativity (10-6) at Cycle 6 MRD-negativity rate was defined as the proportion of patients who achieved MRD negativity (10-4). regardless of response. MRD-evaluable population defined as those patients with an available MRD test with a positive or negative result (excluding those who were not tested, were indeterminate, or had no baseline clone detected [NGS]). One patient had discontinued after completing Cycle 3. One patient had discontinued before completing Cycle 3, and 1 had no baseline clone detected for NGS. *Patients who achieved MRD negativity at 10-⁵ or 10-4 at any time on study (post-induction cycle 3 or cycle 6). D, daratumumab; DSMM, Deutsche Studiengruppe Multiples Myelom; GMMG, German-speaking Myeloma Multicenter Group; MRD, minimal residual disease; NGF, next-generation flow cytometry; NGS, next-generation sequencing; QW, weekly, Q4W, every 4 weeks; R, lenalidomide; Tec, teclistamab; V, bortezomib. 14 Presented by MS Raab at the 22nd International Myeloma Society (IMS) Annual Meeting: September 17-20, 2025; Toronto, Canada